Haemochromatosis
Iron overload (hereditary HFE / secondary) → multi-organ deposition
Overview
Iron overload — hereditary (autosomal-recessive HFE mutations, commonest in those of northern European descent) or secondary (repeated transfusion). Iron deposits in liver, pancreas, heart, joints, skin and gonads. Classic late triad: 'bronze diabetes' + hepatomegaly/cirrhosis. Diagnosed by raised ferritin and transferrin saturation; treated by venesection.
Recognise
- Fatigue, arthralgia (2nd/3rd MCP joints), erectile dysfunction/loss of libido (hypogonadism)
- Skin bronzing/slate-grey pigmentation, DIABETES ('bronze diabetes'), hepatomegaly → cirrhosis, cardiomyopathy/arrhythmia
- Raised ferritin AND raised TRANSFERRIN SATURATION (the key early markers)
Red flags
- Cirrhosis → hepatocellular carcinoma risk (surveillance); cardiomyopathy/arrhythmia
- First-degree relatives need screening (HFE genetics + iron studies)
Differentials & how to tell them apart
Investigations
Transferrin saturation (raised, >45%) and ferritin (raised) → HFE genetic testing (C282Y/H63D). Liver assessment (LFTs, fibrosis/elastography, MRI/biopsy for iron/cirrhosis); glucose; cardiac/endocrine evaluation.
Management
Regular venesection (chelation if transfusion-related)
- 1Confirm with transferrin saturation + ferritin → HFE genetics; assess organ damage (liver, glucose, heart). Treat hereditary disease with regular VENESECTION to deplete iron.Gate: Ferritin alone is non-specific (acute-phase) — use TRANSFERRIN SATURATION to confirm true iron overload; secondary (transfusional) overload needs CHELATION, not venesection; screen first-degree relatives
- 2Maintenance venesection; HCC surveillance if cirrhotic; manage diabetes/cardiomyopathy/hypogonadism; screen and counsel family.
Key points
Fatigue + arthralgia + bronze skin + diabetes + deranged LFTs = think haemochromatosis → transferrin saturation + ferritin → HFE → venesect. 'Bronze diabetes'. Don't be fooled by ferritin alone (acute-phase).
Monitor & prognosis
Ferritin/transferrin saturation; LFTs; HCC surveillance.
Normal life expectancy if treated before cirrhosis.
Source: BSG; Society for Endocrinology